139 related articles for article (PubMed ID: 38485057)
1. Activated sputum eosinophils associated with exacerbations in children on mepolizumab.
Wilson GE; Knight J; Liu Q; Shelar A; Stewart E; Wang X; Yan X; Sanders J; Visness C; Gill M; Gruchalla R; Liu AH; Kattan M; Khurana Hershey GK; Togias A; Becker PM; Altman MC; Busse WW; Jackson DJ; Montgomery RR; Chupp GL
J Allergy Clin Immunol; 2024 Mar; ():. PubMed ID: 38485057
[TBL] [Abstract][Full Text] [Related]
2. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
[TBL] [Abstract][Full Text] [Related]
4. Blood CD62L
Vultaggio A; Accinno M; Vivarelli E; Mecheri V; Maggiore G; Cosmi L; Parronchi P; Rossi O; Maggi E; Gallo O; Matucci A
Allergy; 2023 Dec; 78(12):3154-3165. PubMed ID: 37792721
[TBL] [Abstract][Full Text] [Related]
5. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
[TBL] [Abstract][Full Text] [Related]
6. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.
Kelly EA; Esnault S; Liu LY; Evans MD; Johansson MW; Mathur S; Mosher DF; Denlinger LC; Jarjour NN
Am J Respir Crit Care Med; 2017 Dec; 196(11):1385-1395. PubMed ID: 28862877
[TBL] [Abstract][Full Text] [Related]
7. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
8. Mepolizumab and exacerbations of refractory eosinophilic asthma.
Haldar P; Brightling CE; Hargadon B; Gupta S; Monteiro W; Sousa A; Marshall RP; Bradding P; Green RH; Wardlaw AJ; Pavord ID
N Engl J Med; 2009 Mar; 360(10):973-84. PubMed ID: 19264686
[TBL] [Abstract][Full Text] [Related]
9. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial.
Jackson DJ; Bacharier LB; Gergen PJ; Gagalis L; Calatroni A; Wellford S; Gill MA; Stokes J; Liu AH; Gruchalla RS; Cohen RT; Makhija M; Khurana Hershey GK; O'Connor GT; Pongracic JA; Sherenian MG; Rivera-Spoljaric K; Zoratti EM; Teach SJ; Kattan M; Dutmer CM; Kim H; Lamm C; Sheehan WJ; Segnitz RM; Dill-McFarland KA; Visness CM; Becker PM; Gern JE; Sorkness CA; Busse WW; Altman MC;
Lancet; 2022 Aug; 400(10351):502-511. PubMed ID: 35964610
[TBL] [Abstract][Full Text] [Related]
10. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
11. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab versus placebo for asthma.
Powell C; Milan SJ; Dwan K; Bax L; Walters N
Cochrane Database Syst Rev; 2015 Jul; (7):CD010834. PubMed ID: 26214266
[TBL] [Abstract][Full Text] [Related]
13. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
Katz LE; Gleich GJ; Hartley BF; Yancey SW; Ortega HG
Ann Am Thorac Soc; 2014 May; 11(4):531-6. PubMed ID: 24606022
[TBL] [Abstract][Full Text] [Related]
14. Anti-IL-5 therapies for asthma.
Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
[TBL] [Abstract][Full Text] [Related]
15. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
[TBL] [Abstract][Full Text] [Related]
16. Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma-A Randomized, Placebo-Controlled Crossover Trial (MAPLE).
Yang F; Busby J; Heaney LG; Pavord ID; Brightling CE; Borg K; McDowell JP; Diver SE; Shrimanker R; Bradding P; Shepherd M; Chaudhuri R;
J Allergy Clin Immunol Pract; 2022 Nov; 10(11):2925-2934.e12. PubMed ID: 35863669
[TBL] [Abstract][Full Text] [Related]
17. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults.
Petsky HL; Li A; Chang AB
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD005603. PubMed ID: 28837221
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials.
Liu Y; Zhang S; Li DW; Jiang SJ
PLoS One; 2013; 8(3):e59872. PubMed ID: 23544105
[TBL] [Abstract][Full Text] [Related]
19. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
20. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
